Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov 15;63(4):1077-82.
doi: 10.1016/j.ijrobp.2005.04.040. Epub 2005 Jul 18.

Comparison of Late Toxicity Between Continuous Low-Dose-Rate and Pulsed-Dose-Rate Brachytherapy in Cervical Cancer Patients

Affiliations

Comparison of Late Toxicity Between Continuous Low-Dose-Rate and Pulsed-Dose-Rate Brachytherapy in Cervical Cancer Patients

Barbara Bachtiary et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: To compare survival and severe late radiation toxicity between patients who received continuous low-dose-rate (LDR) brachytherapy (BT) and pulsed-dose-rate (PDR) BT for cervical cancer.

Methods and materials: A retrospective review of cervical cancer patients who underwent primary radiotherapy with or without concurrent cisplatin was performed. Late Grade 3 or worse toxicities were assessed using the National Cancer Institute Common Toxicity Criteria. The study endpoints were overall and disease-free survival and the probability of severe late toxicity.

Results: A total of 109 patients (65.7%) received LDR BT and 57 (34.3%) received PDR BT. Seventy patients received concurrent chemotherapy with cisplatin. The 3-year overall survival and disease-free survival rate was 70% and 57% for the LDR group and 82% and 70% for the PDR group, respectively (p = 0.25 and p = 0.19). The 3-year probability rate for late Grade 3 or worse toxicity was 7.4% for LDR BT patients and 7.6% for PDR BT patients, respectively (p = 0.69) and 6.9% and 7.6%, respectively, for concurrent chemotherapy vs. none (p = 0.69).

Conclusion: No difference was found in severe late toxicity, overall survival, or disease-free survival between the LDR and PDR groups.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles
Feedback